Cardiothoracic
Conference Coverage
Low-risk TAVR loses ground at 2 years in PARTNER 3
Conference Coverage
Radial arteries show CABG survival advantage over saphenous veins
For the first time, an arterial alternative to saphenous vein grafts produced a survival benefit when used as the second CABG conduit.
Conference Coverage
Outcomes-based measurement of TAVR program quality goes live
The ACC and STS team that runs the mandated U.S. national TAVR registry devised and is launching a new metric to measure program quality.
Conference Coverage
UK TAVI: Similar outcomes to surgery in real world
The trial confirms that the results of previous trials in low- to intermediate-risk patients can also be replicated in real-world clinical...
Conference Coverage
Novel mitral valve device shows encouraging mortality data
At 3 years, a novel annuloplasty device for mitral valve regurgitation is associated with low relative mortality.
Feature
Societies dig in to EXCEL trial controversy
EACTS-ESC calls for evidence review and development of updated recommendations for left-main disease “as a matter of urgency.”
Conference Coverage
Health benefits of TAVR over SAVR sustained at 1 year
SAN FRANCISCO – This marks the first randomized trial to show a persistent, albeit modest, disease-specific health status advantage with TAVR at 6...
Conference Coverage
Volume directly tied to mitral valve procedure success
SAN FRANCISCO – The magic number for physicians is 35 cases per year.
Conference Coverage
Fibrinogen concentrate effective, safe for postop bleeding
SAN ANTONIO – Favored more in Europe than North America, fibrinogen concentrate was noninferior to cryoprecipitate for control of bleeding after...
Conference Coverage
Strong showing for TAVR after 5 years in PARTNER 2A
SAN FRANCISCO – In patients without acceptable transfemoral access, surgery may be the preferred alternative, Dr. Vinod H. Thourani said.
Conference Coverage
Race mismatch may affect survival in lung transplant setting
NEW ORLEANS – If it’s an option, clinicians should consider donor-to-recipient race compatibility.